Biogen (NASDAQ:BIIB) Given Hold Rating at Needham & Company LLC
Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Needham & ...
Biogen (BIIB) Receives a Buy from Evercore ISI
Evercore ISI analyst Umer Raffat maintained a Buy rating on Biogen (BIIB – Research Report) yesterday. The company’s shares closed yesterday at ...
Biogen Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
BioPharma Dive2d
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.
Biogen price target lowered to $224 from $244 at Scotiabank
Scotiabank lowered the firm’s price target on Biogen (BIIB) to $224 from $244 and keeps an Outperform rating on the shares. Fiscal year results ...